Brief: Active Biotech Announces New Direction
05/02/2020 08:43
Feb 5 (Reuters) - Active Biotech AB ACTI.ST :
* REG-ACTIVE BIOTECH ANNOUNCES NEW DIRECTION
* BOARD OF DIRECTORS, HAS APPROVED A NEW DIRECTION FOR
COMPANY.
* TASQUINIMOD WILL BE ADVANCED IN A NEW ACADEMIC
PARTNERSHIP, AS
AN IMMUNOMODULATORY PRODUCT WITH A NOVEL MECHANISM OF ACTION,
FOR TREATMENT OF MULTIPLE MYELOMA
* NO FURTHER WORK ON PRIOR CLINICAL PROGRAMS WITHIN MULTIPLE
SCLEROSIS OR HUNTINGTON'S DISEASE FOR LAQUINIMOD OR SOLID TUMORS
FOR TASQUINIMOD WILL BE UNDERTAKEN
* TASQUINIMOD WILL BE ADVANCED AS A NEW PRODUCT FOR
TREATMENT OF
MULTIPLE MYELOMA
* AT YEAR-END 2019 AVAILABLE CASH IS SCHEDULED TO FINANCE
ONGOING
ACTIVITIES IN NEW DIRECTION THROUGH 2021
* LAQUINIMOD AS A NEW PRODUCT IN CROHN'S DISEASE
* LAQUINIMOD AS A NEW PRODUCT FOR USE IN EYE DISORDERS
Source text for Eikon: ID:nGNE9RwklQ
Further company coverage: ACTI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))